Litigation

Recent Posts

Jury Awards Plaintiff $8 Million In Fosamax Lawsuit
Posted on 29 Jun 2010 by Tom Moylan

NEW YORK - (Mealey's) A jury returned an $8 million compensatory damages verdict against Merck & Co. Inc. on June 25 in the U.S. District Court for the Southern District of New York in the retrial of the first Fosamax multidistrict litigation... Read More

Tags: osteonecrosis of the jaw , Merck & Co. Inc. , personal injury , ONJ , Shirley Boles v. Merck & Co. , Litigation , multidistrict litigation , lawsuit , Shirley Boles , Fosamax , torts , osteoporosis , In Re: Fosamax Products Liability Litigation

$8M Fosamax Verdict Remitted By MDL Judge To $1.5M Or New Damages Trial
Posted on 5 Oct 2010 by Tom Moylan

NEW YORK -- (Mealey's) The New York federal judge overseeing the Fosamax multidistrict litigation on Oct. 4 sua sponte found that an $8 million verdict in a bellwether trial is excessive and ordered a remittitur of the verdict to $1.5 million unless... Read More

Tags: Douglas & London , punitive damages , Damages , bisphosphonate , osteonecrosis of the jaw , personal injury , Judge John F. Keenan , product liability , Trial , MDL. Shirley Boles v. Merck & Co. , ONJ , Merck , Litigation , osteoporosis drug , multidistrict litigation , Fosamax multidistrict litigation , lawsuit , Shirley Boles , Fosamax , verdict , torts , Gary Douglas , In Re: Fosamax Products Liability Litigation

Fosamax MDL Jury: Drug Wasn't Defectively Designed, Didn't Cause Jaw Injury
Posted on 3 Oct 2011 by Tom Moylan

NEW YORK - A New York federal jury hearing the fourth Fosamax bellwether trial on Oct. 3 found that Merck's osteoporosis drug was not defectively designed and did not cause a plaintiff to develop osteonecrosis of the jaw (ONJ) ( In Re: Fosamax Products... Read More

Tags: osteonecrosis of the jaw , ONJ , Linda Secrest , Merck , drugs and devices , Litigation , osteoporosis drug , Linda Secrest v. Merck &amp , In Re: Fosamax Products Liability Litigation

Merck To Settle Suits Alleging Jaw Damage From Osteoporosis Drug
Posted on 10 Dec 2013 by Michael Lefkowitz

WHITEHOUSE STATION, N.J. — (Mealey's) Merck & Co. Inc. has agreed to pay $27.7 million to resolve product liability suits alleging that its osteoporosis drug Fosamax caused osteonecrosis of the jaw (ONJ), or bone death, according to a press... Read More

Tags: New York , drugs , Judicial Panel on Multidistrict Litigation , osteonecrosis of the jaw , product liability , Fosama , ONJ , Litigation , osteoporosis drug , Merck & Co. , bone death , In Re: Fosamax Products Liability Litigation